{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["78(2)"],"submitter":["Gauvreau GM"],"funding":["AstraZeneca Canada"],"pubmed_abstract":["The alarmin cytokines thymic stromal lymphopoietin (TSLP), interleukin (IL)-33, and IL-25 are epithelial cell-derived mediators that contribute to the pathobiology and pathophysiology of asthma. Released from airway epithelial cells exposed to environmental triggers, the alarmins drive airway inflammation through the release of predominantly T2 cytokines from multiple effector cells. The upstream positioning of the alarmins is an attractive pharmacological target to block multiple T2 pathways important in asthma. Blocking the function of TSLP inhibits allergen-induced responses including bronchoconstriction, airway hyperresponsiveness, and inflammation, and subsequent clinical trials of an anti-TSLP monoclonal antibody, tezepelumab, in asthma patients demonstrated improvements in lung func"],"journal":["Allergy"],"pagination":["402-417"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10108333"],"repository":["biostudies-literature"],"pubmed_title":["Sounding the alarmins-The role of alarmin cytokines in asthma."],"pmcid":["PMC10108333"],"pubmed_authors":["Boulet LP","Davis BE","Leigh R","O'Byrne PM","Cockcroft DW","Cote A","Gauvreau GM","Myers I","Bergeron C","Sehmi R"],"additional_accession":[]},"is_claimable":false,"name":"Sounding the alarmins-The role of alarmin cytokines in asthma.","description":"The alarmin cytokines thymic stromal lymphopoietin (TSLP), interleukin (IL)-33, and IL-25 are epithelial cell-derived mediators that contribute to the pathobiology and pathophysiology of asthma. Released from airway epithelial cells exposed to environmental triggers, the alarmins drive airway inflammation through the release of predominantly T2 cytokines from multiple effector cells. The upstream positioning of the alarmins is an attractive pharmacological target to block multiple T2 pathways important in asthma. Blocking the function of TSLP inhibits allergen-induced responses including bronchoconstriction, airway hyperresponsiveness, and inflammation, and subsequent clinical trials of an anti-TSLP monoclonal antibody, tezepelumab, in asthma patients demonstrated improvements in lung func","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-04-18T20:19:43.289Z","creation":"2024-11-20T08:02:29.635Z"},"accession":"S-EPMC10108333","cross_references":{"pubmed":["36463491"],"doi":["10.1111/all.15609"]}}